Validea Detailed Fundamental Analysis

Thermo Fisher Scientific (TMO), a large-cap growth stock in the Medical Equipment & Supplies sector, received a 66% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy for identifying low book-to-market stocks with sustained growth potential. While this score is below the 80% threshold typically indicating interest, TMO passed several key growth criteria including Book/Market Ratio, Return on Assets, and Sales Variance, though it failed on metrics related to Advertising, Capital Expenditures, and R&D relative to assets, presenting a mixed fundamental picture within this specific growth framework.

Analysis

Thermo Fisher Scientific (TMO) receives a mixed evaluation under Validea's P/B Growth Investor model, which is based on Partha Mohanram's strategy for identifying low book-to-market stocks with sustained growth potential. The company achieved a score of 66%, a rating that falls short of the 80% threshold typically indicating model interest. On the positive side, TMO passed several key fundamental tests, including its Book/Market Ratio, Return on Assets (ROA), and Cash Flow from Operations to Assets, signaling a solid foundation in terms of valuation, profitability, and cash generation. Furthermore, the company passed criteria for ROA Variance and Sales Variance, suggesting stability in its financial performance. However, the model flags significant weaknesses by failing TMO on its investment in future growth drivers. Specifically, the company's ratios for Advertising to Assets, Capital Expenditures to Assets, and Research and Development to Assets did not meet the strategy's criteria, raising questions about the sustainability of its growth trajectory from this model's perspective.

Key Decisions for Investors

• Investors seeking aggressive, sustained growth should note the model's specific concerns regarding TMO's lower-than-desired investment in R&D, capital expenditures, and advertising relative to its asset base.
• The stock's positive performance on profitability, cash flow, and valuation metrics may appeal to 'Growth at a Reasonable Price' (GARP) investors who prioritize current financial health over high-growth spending.
• Given the overall score of 66% is below the model's 80% interest threshold, this specific analysis does not present a strong buy signal; investors may consider this a neutral data point and seek confirmation from other valuation frameworks before initiating or adding to a position.